Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$4.35 +8.8%	$4.98	$3.39 ▼ $16.00	$47.10M	0.87	54,937 shs	139,388 shs
KPTI Karyopharm Therapeutics	$4.12 -1.9%	$5.03	$3.51 ▼ $17.40	$35.60M	0.33	82,212 shs	109,551 shs
NERV Minerva Neurosciences	$1.56 +1.3%	$1.57	$1.15 ▼ $3.69	$10.91M	-0.5	27,984 shs	18,312 shs
SPRO Spero Therapeutics	$2.74 +9.6%	$0.77	$0.51 ▼ $2.93	$153.20M	0.23	1.07 million shs	6.58 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	0.00%	+5.33%	-21.63%	-41.04%	-66.20%
KPTI Karyopharm Therapeutics	0.00%	-6.32%	-41.58%	-40.69%	-70.42%
NERV Minerva Neurosciences	0.00%	+5.89%	-9.06%	+1.05%	-39.37%
SPRO Spero Therapeutics	0.00%	+270.53%	+298.76%	+235.02%	+81.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	2.9323 of 5 stars	3.5	3.0	0.0	2.6	1.7	1.3
KPTI Karyopharm Therapeutics	3.8829 of 5 stars	3.5	0.0	4.6	3.0	2.5	0.6
NERV Minerva Neurosciences	3.5235 of 5 stars	3.0	3.0	4.6	3.3	0.0	0.0
SPRO Spero Therapeutics	3.7684 of 5 stars	3.3	3.0	4.7	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	3.00	Buy	$30.00	589.66% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	948.54% Upside
NERV Minerva Neurosciences	2.00	Hold	$5.00	220.51% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	82.48% Upside

Current Analyst Ratings Breakdown

Latest NERV, AVTX, KPTI, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
3/25/2025	AVTX Avalo Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform ➝ Buy	$23.00
3/25/2025	AVTX Avalo Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$36.00
3/20/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/20/2025	AVTX Avalo Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$18.00
3/3/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$75.00 ➝ $54.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$441K	106.81	N/A	N/A	$9.11 per share	0.48
KPTI Karyopharm Therapeutics	$142.13M	0.25	N/A	N/A	($1.47) per share	-2.80
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.07) per share	N/A
SPRO Spero Therapeutics	$28.30M	5.41	$1.69 per share	1.62	$2.02 per share	1.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$31.54M	N/A	0.00	N/A	N/A	N/A	-442.16%	122.99%	8/11/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$143.10M	-$13.26	N/A	N/A	N/A	-52.62%	N/A	-39.58%	8/5/2025 (Estimated)
NERV Minerva Neurosciences	-$30M	$0.82	N/A	N/A	N/A	N/A	N/A	-6.74%	8/5/2025 (Estimated)
SPRO Spero Therapeutics	$22.81M	-$1.28	39.15	N/A	N/A	3.30%	4.03%	2.21%	8/4/2025 (Estimated)

Latest NERV, AVTX, KPTI, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	NERV Minerva Neurosciences	-$1.07	-$0.50	+$0.57	-$0.50	N/A	N/A
5/13/2025	Q1 2025	SPRO Spero Therapeutics	-$0.55	-$0.25	+$0.30	-$0.25	$11.00 million	$5.87 million
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
3/27/2025	Q4 2024	SPRO Spero Therapeutics	-$0.35	-$0.38	-$0.03	-$0.38	$12.40 million	$15.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	$0.06	2.19%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	1.42	1.42
KPTI Karyopharm Therapeutics	N/A	1.70	2.93
NERV Minerva Neurosciences	N/A	6.23	6.23
SPRO Spero Therapeutics	N/A	2.68	2.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
KPTI Karyopharm Therapeutics	66.44%
NERV Minerva Neurosciences	34.56%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	3.03%
KPTI Karyopharm Therapeutics	2.98%
NERV Minerva Neurosciences	8.60%
SPRO Spero Therapeutics	4.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.37 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	122.72 million	Optionable
NERV Minerva Neurosciences	9	6.99 million	6.39 million	Not Optionable
SPRO Spero Therapeutics	150	55.91 million	52.05 million	Optionable

NERV, AVTX, KPTI, and SPRO Headlines

Recent News About These Companies

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31 at 2:12 PM | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31 at 10:19 AM | insidermonkey.com

Best Penny Stocks To Watch Today - May 28th

May 30 at 4:08 PM | marketbeat.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30 at 5:33 AM | pharmabiz.com

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 30 at 12:33 AM | thepharmaletter.com

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 30 at 12:33 AM | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

Spero Therapeutics Sees Unusually Large Options Volume (NASDAQ:SPRO)

May 29, 2025 | marketbeat.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.com

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.com

Spero Therapeutics Shares Soar as Trial with GSK Ends Early on Efficacy

May 28, 2025 | marketwatch.com

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results

May 28, 2025 | msn.com

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28, 2025 | globenewswire.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 13, 2025 | globenewswire.com

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

May 5, 2025 | globenewswire.com

Spero Therapeutics, Inc.: Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 29, 2025 | finanznachrichten.de

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

April 28, 2025 | globenewswire.com

Spero Therapeutics Analyst Ratings

April 7, 2025 | benzinga.com

TD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)

April 2, 2025 | markets.businessinsider.com

We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

March 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV, AVTX, KPTI, and SPRO Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$4.35 +0.35 (+8.75%)

Closing price 04:00 PM Eastern

Extended Trading

$4.46 +0.12 (+2.64%)

As of 06:49 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Karyopharm Therapeutics NASDAQ:KPTI

$4.12 -0.08 (-1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$4.12 +0.00 (+0.12%)

As of 05:11 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Minerva Neurosciences NASDAQ:NERV

$1.56 +0.02 (+1.30%)

Closing price 03:55 PM Eastern

Extended Trading

$1.58 +0.02 (+1.60%)

As of 04:02 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Spero Therapeutics NASDAQ:SPRO

$2.74 +0.24 (+9.60%)

Closing price 04:00 PM Eastern

Extended Trading

$2.76 +0.02 (+0.91%)

As of 07:03 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time